Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Kizzmekia Corbett and Ralph Baric.
Kizzmekia Corbett
Connection Strength
0.802
Ralph Baric
  1. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020 10; 586(7830):567-571.
    View in: PubMed
    Score: 0.224
  2. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med. 2020 10 15; 383(16):1544-1555.
    View in: PubMed
    Score: 0.224
  3. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science. 2021 09 17; 373(6561):1372-1377.
    View in: PubMed
    Score: 0.060
  4. COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. Immunity. 2021 08 10; 54(8):1869-1882.e6.
    View in: PubMed
    Score: 0.060
  5. Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. Science. 2021 Aug 13; 373(6556).
    View in: PubMed
    Score: 0.060
  6. SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques. Sci Immunol. 2021 06 15; 6(60).
    View in: PubMed
    Score: 0.059
  7. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci Transl Med. 2021 05 12; 13(593).
    View in: PubMed
    Score: 0.059
  8. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med. 2020 12 17; 383(25):2427-2438.
    View in: PubMed
    Score: 0.057
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.